4-benzamido-1-[2-(3-indolyl)ethyl]-pyridinium bromide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-benzamido-1-[2-(3-indolyl)ethyl]-pyridinium bromide
• 英文别名: 4-benzamido-1-[2-(3-indolyl)ethyl] pyridinium bromide；4-Benzamido-1-[2-(3-indolyl)ethyl]pyridinium bromide；4-Benzamido-1-[2-(3-indolyl)ethyl]pyridiniumbromide；N-[1-[2-(1H-indol-3-yl)ethyl]pyridin-1-ium-4-yl]benzamide;bromide
• 化学式: Br*C₂₂H₂₀N₃O
• 分子量: 422.324
• InChiKey: ITHIIWSDRXWJCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.95
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  48.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-benzamido-1-[2-(3-indolyl)ethyl]-pyridinium bromide 在 sodium borohydrid 作用下， 以 仲丁醇 为溶剂， 生成 吲哚拉明
  参考文献：
  名称：

  Process for preparing 3-[(benzamidopiperid-1-yl)alkyl] indoles

  摘要：

  本发明提供了一种制备吲哚的新工艺，其中使用特殊溶剂将4-酰胺基-1-[3-吲哚基-亚烯基]吡啶化合物或相应的四氢吡啶化合物还原为相应的哌啶化合物。

  公开号：

  US04162252A1

文献信息

• USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA
  申请人：——

  公开号：US20020032219A1

  公开（公告）日：2002-03-14

  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr; 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr; 1A adrenergic receptor, a human &agr; 1B adrenergic receptor, and a human histamine H 1 receptor, and, binds to a human &agr; 2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr; 1C adrenergic receptor. Compounds meeting these criteria are provided.

  一种治疗良性前列腺增生症的方法，包括向患者施用一种治疗有效量的化合物，该化合物与人类α1C肾上腺素受体结合的亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组胺H1受体结合的亲和力高出十倍以上，并且与人类α2肾上腺素受体结合的亲和力比其与α1C肾上腺素受体结合的亲和力低十倍以上。提供符合这些标准的化合物。
• Compositions comprising alpha-1C specific compounds
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20030022900A1

  公开（公告）日：2003-01-30

  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr; 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr; 1A adrenergic receptor, a human &agr; 1B adrenergic receptor, and a human histamine H 1 receptor, and, binds to a human &agr; 2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr; 1C adrenergic receptor. Compounds meeting these criteria are provided.

  一种治疗良性前列腺增生的方法，包括向患者施用一种与人类α1C肾上腺素能受体结合的化合物，其结合亲和力比其与人类α1A肾上腺素能受体、人类α1B肾上腺素能受体和人类组胺H1受体结合的亲和力高出十倍以上，并且与人类α2肾上腺素能受体的结合亲和力比其与该α1C肾上腺素能受体结合的亲和力低十倍以上。提供了符合这些标准的化合物。
• DNA encoding human alpha 1 adrenergic receptors and uses thereof
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20030113771A1

  公开（公告）日：2003-06-19

  This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.

  本发明提供了编码和表达正常或突变的α1a、α1b和α1c肾上腺素受体基因的分离核酸、载体、转化的哺乳动物细胞和非人类转基因动物。本发明还提供了一种蛋白质和针对该蛋白质的抗体，以及与α1a、α1b和α1c肾上腺素受体相关的药物化合物。本发明提供了与α1a、α1b和α1c肾上腺素受体基因互补的核酸探针和反义寡核苷酸。此外，本发明还提供了用于确定配体结合、检测表达、药物筛选和治疗与人类α1a、α1b和α1c肾上腺素受体相关的异常的方法。
• DNA ENCODING HUMAN ALPHA 1 ADRENERGIC RECEPTORS AND USES THEREOF
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：EP0663014A1

  公开（公告）日：1995-07-19
• EP0663014A4
  申请人：——

  公开号：EP0663014A4

  公开（公告）日：1997-06-11